Skip to main content
Download PDF

Analyzing the effects of barriers to and facilitators of medication adherence among patients with cardiometabolic diseases: a structural equation modeling approach

BMC Health Services Research volume 22, Article number: 588 (2022) Cite this article

Abstract

Background

Based on the theoretical model of medication adherence (WHO, 2003), the aims of the study were (1) to develop and test a theory-based multidimensional model for the predictive power of barriers to and facilitators of medication adherence and (2) to identify the mediating effects of barriers to medication adherence on drug-related patient outcomes (barrier “MedAd- “: forget; facilitator “MedAd + ”: regular intake).

Methods

Within a cross-sectional study entitled “Increasing medication adherence to improve patient safety in cardiological rehabilitation (PaSiMed)”, the model was evaluated in structural analytical terms based on data collected online of N = 225 patients with cardiometabolic diseases. The revised “Freiburg questionnaire on medication adherence (FF-MedAd-R)" was used to measure the latent constructs (e.g., facilitator: communication; barrier: reservations).”

Results

The structural equation model proved to exhibit an appropriate data fit (RMSEA: .05; CFI: .92). For all first-order facilitators of medication adherence, a high proportion of variance (62–94%) could be explained by the second-order factor “Physician–patient relationship (PPR)”. All paths from “PPR” to the constructs depicting barriers to medication adherence showed significant negative effects. Facilitators (“MedAd + ”) and barriers (“MedAd-”) accounted for 20% and 12% of the variance, respectively, in global items of medication adherence. Whereas “Carelessness” showed a full mediation for “MedAd-”, ‘‘Reservations’’ showed a partial mediation for “MedAd + ”.

Conclusions

“PPR” is an important predictor of patient medication adherence. The results underline the importance of a trustful physician–patient relationship in reducing barriers and enhancing medication adherence.

Peer Review reports

Introduction

Cardiovascular diseases are the most common cause of death in the industrialized world [1]. Despite the known relationship between cardiometabolic diseases (hypertension [2, 3], diabetes mellitus [4, 5], hyperlipoproteinemia [6, 7]) and elevated cardiovascular morbidity [8, 9] and mortality [10,11,12,13], patients often exhibit poor metabolic [5, 13] and blood pressure [14, 15] control. In addition, according to World Health Organization (WHO) estimates, only approximately 50% of all people with chronic diseases take their long-term medications regularly [16]. Increasing medication adherence is thought to reduce cardiovascular morbidity [17] and mortality [10] and to achieve economically significant reductions in health care costs [18].

In contrast to the term “compliance” (representing a more paternalistic view [19]), adherence is defined by the WHO [16] as “the extent to which a person’s behavior-taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider” and explicitly incorporates the provider’s responsibility for establishing a good provider-patient relationship as well as for actively involving patients. In general, sufficient adherence is considered to be achieved when at least 80% of medically prescribed medicines are taken regularly [20, 21].

Medication adherence is a complex and dynamic system of different and interrelated influencing factors [16, 22] that can facilitate or hinder the experience and behavior of chronically ill people. As potential causes of poor medication adherence, the WHO lists socioeconomic (e.g. costs), system-related (e.g., insufficient communication), disease-related (e.g., specific problems), therapy-related (e.g., therapy complexity) and patient-related factors (e.g., forget, reservations) [16]. In addition to a good physician–patient relationship (e.g. [22,23,24,25]), effective measures to enhance medication adherence include reducing drug complexity [1, 19, 26], promoting self-management (e.g., patient education [27]), and regular contact (e.g., text messages [1, 28]) as part of multidisciplinary care [29].

In addition, it is thought that the mutual exchange of information between physicians and patients (e.g., “Shared decision making (SDM)” [30]) may lead to higher medication adherence [19, 31]. However, existing study results on the effect of “SDM” on the medication adherence of people with cardiometabolic diseases are inconsistent. While in one study a positive effect was observed for a subgroup of patients who had a particularly high need for participation [31], other studies showed no effect [32] or a negative effect [24].

Existing studies have mostly singled out individual aspects of medication adherence and examined them in more detail (e.g., patient-physician communication [22, 23, 33, 34]). Little is known about interrelationships between facilitators of medication adherence (e.g., communication, trust, informedness) and barriers to medication adherence (e.g., reservations, carelessness [24]). To our knowledge, no study was available that examined associations of several facilitating factors of and barriers to medication adherence based on multiple dimensions of the WHO theory model (system, disease, therapy, patient [16]) using a structural equation model.

Objective of the study

The main objective of this study was to use the WHO theoretical model [16] together with empirical evidence (e.g., [23, 25]) as the basis for developing a theory-based multidimensional model and to test its suitability using empirical data from people with cardiometabolic diseases. The results should contribute to a better understanding of the relationships between different determinants of medication adherence and drug-related patient outcomes (barrier: forget; facilitator: regular intake).

Study background

The study presented here is part of the project entitled “Increasing medication adherence to improve patient safety in cardiological rehabilitation (PaSiMed)”, which consists of a total of three parts.

In the first part, the “Freiburg questionnaire on medication adherence (FF-MedAd)” for surveying barriers to and facilitators of medication adherence was developed in a theory-based manner on a system-based, disease-based, therapy-based, and patient-based level [16]. The “FF-MedAd” was tested psychometrically in a sample of cardiac rehabilitation patients (N = 133) using exploratory factor analysis and reliability analysis [35]. It consists of 2 global items on medication adherence (see Table 1, Rows “MedAd + ”: “I take my medications regularly. “; “MedAd-”: “Sometimes I forget to take my medications.“) and 30 items on 3 facilitators of and 5 barriers to medication adherence (see Table 1, “FF-MedAd”, Column 2). In the second part, interviews on barriers to and facilitators of medication adherence were conducted with cardiac rehabilitation patients (N = 22), subjected to content analysis [25], and used to develop the revised “FF-MedAd-R”. One of the key objectives of the revision was complementing the questionnaire by additional items and dimensions that were identified in the interviews as guiding action and being relevant to everyday life (see Table 1, “Interviews”, Column 3). In the third part of the project reported here, “FF-MedAd-R” was used and subjected to confirmatory testing. In its original version, it consists of 86 items, reflecting 14 factors. Of these factors, 10 represent barriers to and 4 represent facilitators of medication adherence (see Table 1, “FF-MedAd-R”, “CFA model” inclusion, Column 4). All items are scored on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). Higher values correspond to a higher degree of expression of the respective latent constructs or items. A detailed overview of the contents of the items and dimensions can be found in the Additional file 1 (Columns 1–9).

Table 1 Overview of the questionnaire development process at the dimension level
Full size table

Research questions and hypotheses

To answer the main research questions, the following hypotheses were formulated regarding the data fit of the complete model and the construct associations:

Hypothesis I

The data information of the variables can be adequately modeled by a theory-based structural model.

Hypothesis II

The constructs that represent facilitators of medication adherence are independent predictors of “MedAd + ” and “MedAd-”.

Hypothesis III

The constructs that are facilitators of medication adherence are predictive of the constructs representing barriers to medication adherence.

Hypothesis IV

The effects of the independent variables representing facilitators of medication adherence on the dependent variables “MedAd + ” and “MedAd-” are mediated by the variables representing barriers to medication adherence.

Methods

Sample

The data collection took place in a cross-sectional study between September 2020 and February 2021. Participants were patients with cardiometabolic diseases selected via a nationwide self-help organization in Germany [36]. The inclusion criteria for participants were as follows: (1) age ≥ 18 years, (2) long-term medication (> 3 months), (3) hypertension and/or diabetes mellitus and/or hyperlipoproteinemia (self-reported), and (4) confirmation of informed consent. The exclusion criteria for participants with diabetes mellitus were pure insulin therapy because of the need for self-management and self-adjustment as part of the therapy (e.g., intensified insulin therapy). The survey was carried out online using the academic tool “Unipark” [37].

The survey was completed by a total of 234 people. After excluding nine records (n = 1: age < 18 years; n = 8: pure insulin therapy), the final study sample consisted of 225 patients. A description of the sample can be found in Table 2.

Table 2 Characteristics of the sample (N = 225)
Full size table

In addition, detailed information on the medications of the sample can be found in Table 3.

Table 3 Characteristics on the medications of the sample (N = 225)
Full size table

Data analysis

For the 225 patients included in the analysis, a maximum of 3% missing values in the items of the scales was observed. Prior to the main data analyses, these missing values were imputed by the expectation–maximization algorithm, which estimates missing data using an iterative maximum-likelihood procedure [39,40,41]. The imputation was performed with the software NORM [42]. For the descriptive statistics of the scales, SPSS 26.0 for Windows software was used [43]. To estimate the multivariate dependencies, structural equation modeling (SEM) was employed [40, 44]. The maximum likelihood estimation procedure implemented in AMOS 26.0 software [45] was used to develop and test all structural models. In the first step [40], a confirmatory factor analysis (CFA) was performed, assuming that all items are distinct indicators of an underlying latent construct, whereby different constructs are allowed to be correlated. The appropriateness of the CFA model was assessed by measures of global and local fit. Measures of global fit indicate whether the empirical associations among the manifest variables are appropriately reproduced by the model [40]. The chi-square provides the strictest form of global model testing [46, 47] because it requires that all the information in the variance–covariance matrix be explained, except for random effects.

Model assessment is usually based on alternative global fit measures. The root mean square error of approximation (RMSEA) indicates the proportion of variance–covariance information not correctly predicted by the model (acceptable model fit: RMSEA ≤ 0.08; good model fit: ≤ 0.05 [40]). In addition, the comparative fit index (CFI) and the Tucker-Lewis index (TLI) were calculated as measures of incremental fit (acceptable model fit: CFI, TLI: ≥ 0.90; good model fit: ≥ 0.95 [40, 48]). Measures of local fit evaluate whether each construct can be reliably estimated from its indicators [47] and whether the constructs within the model are sufficiently distinguishable [47]. To ensure a solid estimation at the construct level, the following indicators of a local fit were applied: the proportion of variance of the indicators predicted by the construct should amount to > 0.40, and the average proportion of variance measured by the construct should be > 0.50 [40, 49]. As criteria for factor reliability, values > 0.60 are accepted as satisfactory [40, 50]. The internal consistency reliability was evaluated using Cronbach's α (adequate: 0.70; good: 0.80; excellent: 0.90 [40]). To check the discriminant validity, the Fornell-Larcker criterion was used, which requires that each construct being more strongly related to its own indicators than to another model construct [49].

In the second step [40], a path model was specified and evaluated using measures of global fit. The significance of the relationships between the exogenous and endogenous latent variables as well as the amount of variance explained in the endogenous variables were examined. To test the mediation hypotheses, the nonparametric BCa bootstrap procedure [51,52,53] was applied ([95% CI], 1.000 BCa samples).

Results

Confirmatory structural modelling (Hypothesis I)

In the first step, a 14-factor measurement model with a total of 86 items (see Additional file 1, Columns 1–3) was specified. The fit measures depicted in Table 4 show that the data were in part insufficiently explained by the model (e.g., TLI; see Table 4, Row “Original CFA model”).

Table 4 Measures of global fit for all models estimated
Full size table

A detailed model inspection pointed to three major sources of problems in the model structure: (1) high intercorrelations between the latent variables, which represent facilitators of medication adherence (“Informedness” and “Trust incl. SDM”: r = 0.91; “Informedness” and”Communication”: r = 0.83; “Informedness” and “Satisfaction medication”: r = 0.81; “Trust incl. SDM” and “Communication”: r = 0.75; “Trust incl. SDM” and “Satisfaction medication”: r = 0.77; “Communication” and “Satisfaction medication”: r = 0.57), (2) insufficient item-construct associations (low indicator reliabilities: < 0.40 [40]), and (3) substantial residual correlations between individual items. Thus, the following data and theory-driven modifications were defined. First, the second-order factor “Physician–patient-relationship (PPR)” reflected by the 4 first-order factors dimensions “Informedness”, “Trust incl. SDM”, “Communication” and “Satisfaction medication” was defined. In addition, the constructs “Informedness” and “Trust incl. SDM” were merged into the construct “Informedness/Trust incl. SDM”. Second, modification indices indicated substantial pairwise residual correlations. Furthermore, indicator reliabilities of individual items of the constructs “Reservations” (“res3” [fear of side effects]/ “res8” [fear of interactions]), and “Communication” (“comm4″ [understood and taken seriously]/ “comm5″ [inquiries possible]) proved to be insufficient. Accordingly, the construct “Communication” was divided into the theoretically sound interpretable subconstructs “Communication: information” and “Communication: patient-centered”. Moreover, the items “res3″ and “res8″ were split into the subconstruct “Fear of side effects”. Third, a total of 45 items were sequentially eliminated from different constructs due to double loadings on several factors (n = 2) and low indicator reliabilities (n = 43; e.g., single item to “SDM”; see Additional file 1, Column “Item Code”, “sdm”). As a result, the scale “Informedness/Trust incl. SDM” was renamed into “Informedness/Trust”. In the fourth step, a total of three dimensions were removed from the model due to insufficient shared item variances: “Lack of trust” (ltrust1–5: indicator reliabilities < 0.40 each), “Specific problems” and “Forget/mix-up” (AVE < 0.50 [40, 49] each). Accordingly, an acceptable to good fit was achieved for all measures (see Table 4, Row “Modified CFA model”). The measures of local fit for the “Modified CFA model” are summarized in Table 5. The threshold for an acceptable fit of indicator reliability was exceeded by 36 of the totals of 37 items, and the t-values of all factor loadings were significant. The required threshold values for factor reliability for structural equation models (> 0.60 [40, 50]) were exceeded by all scales. The average variance extracted by each construct from the indicators was 0.54 or higher [40, 49]. In addition, the internal consistency of all scales was adequate to excellent [40].

Table 5 Measures of local fit for the “Modified CFA model” (N = 225)
Full size table

Table 6 (upper off-diagonal values) shows that all latent factors can be sufficiently delimited from one another, as the off-diagonal values (correlations) are always lower than the corresponding line and row values (root AVE) in the diagonal (Fornell-Larcker criterion [49]). No significant correlations were found between the factors (1) “Avoidance of drug side effects” and “Reservations” (r = 0.13), “Fear of side effects” (r = 0.08), “Insecurity” (r = 0.04), “Carelessness” (r = 0.12) and “Drug intake in public” (r = 0.13), respectively, and (2) “Carelessness” and “Reservations” (r = 0.07), “Fear of side effects” (r = -0.01), “Insecurity” (r = 0.10) and “Drug intake in public” (r = 0.07), respectively, and (3) “Falsified patient information” and “Drug intake in public” (r = 0.11). All other scales were significantly correlated with each other (see Table 6, lower off-diagonal values).

Table 6 Latent construct correlations (upper off-diagonal values), square root of AVE (bold, diagonal) and scale intercorrelations (lower off-diagonal values)
Full size table

As part of the specification of the path model, the second-order factor “PPR” (see Fig. 1, Predictor 1) with its subdimensions “Informedness/Trust”, “Communication: information”, “Communication: patient-centered” and “Satisfaction medication” was interpreted as facilitators of medication adherence, and all other constructs represented barriers to medication adherence (see Fig. 1, Mediator variables). The two global items of medication adherence (see Table 1, Rows “MedAd + ” and “MedAd-”) were added as dependent variables in the path model (see Fig. 1, Patient outcomes). Following the WHO definition of medication adherence [16], the single item of “SDM” was reintegrated in the model (“I have developed my treatment plan together with my physician.”) (see Fig. 1, Predictor 2). An overview of the final dimensions in the “Full path model” can be found in Table 1 (“FF-MedAd-R”, “Full path model” result, Columns 5 and 6). A detailed overview at the item level is shown in the Additional file 1 (Remaining items in the "Full path model", Column 10).

Fig. 1
figure 1

„Full path model “: estimated (only significant) coefficients, mediating effects and percentage of explained variance for the endogenous structural variables. Note: aPPR = Physician patient-relationship; bSDM = Shared decision making; single item: "I have developed my treatment plan together with my physician."; c"MedAd + ": Global item on facilitators of medication adherence: "I take my medications regularly."; d"MedAd-": Global item on barriers to medication adherence: "Sometimes I forget to take my medications". Interpretation according to product–moment correlation (standardized solution): |b|= .1 (weak effect); |b|= .3 (moderate effect); |b|= .5 (strong effect)

Full size image

After allowing for the correlation of 8 error terms between factors that represented barriers to medication adherence (e.g., “Reservations”/ “Fear of side effects”; “Individual decisions”/ “Avoidance of drug side effects”) and the correlation of two error terms within the second-order factor “PPR” (“smed8” [medications really help me]/ “Communication: patient-centered”; “info9” [consequences of stopping]/ “Communication: information”), the measures of global model fit indicate a satisfactory to good model fit (see Table 4, Row ‘‘Full path model’’; Hypothesis I).

Figure 1 shows the corresponding model with the resulting parameter estimations of the standardized solution and information on explained variance. Paths were estimated from the predictors to all mediator variables and both outcomes and from all mediator variables to both outcomes. To enable a better overview, only the significant paths are illustrated.

Additionally, the estimates of direct paths are documented in detail in Table 7.

Table 7 Direct effects of the “Full path model” (standardized path coefficients of the model)
Full size table

Prediction of “MedAd + ” and “MedAd- “ by facilitators (Hypothesis II)

For the “Full path model”, it can be summarized that the predictors “PPR” and “SDM” are positively and significantly correlated (r = 0.49; C.R. = 5.93; p < 0.001). Moreover, “PPR” is an independent predictor of “MedAd + ” (ß = 0.48; C.R. = 4.21; p < 0.001) but does not provide any predictive value for “MedAd-” (ß = -0.01; C.R. = -0.06; p = 0.952). On the other hand, “SDM” showed no significant relationship with “MedAd + ” (ß = -0.06; C.R. = -0.79; p = 0.429) and “MedAd-” (ß = -0.04; C.R. = -0.54; p = 0.591) (see Table 7; Hypothesis II).

Prediction of barriers by facilitators (Hypothesis III)

All direct paths from ‘‘PPR’’ to the constructs representing barriers to medication adherence proved to be significant and pointed in the assumed direction: “Reservations” (ß = -0.56; C.R. = -6.03; p < 0.001), “Fear of side effects” (ß = -0.44; C.R. = -4.76; p < 0.001), “Individual decisions” (ß = -0.47; C.R. = -4.82; p < 0.001), “Avoidance of drug side effects” (ß = -0.22; C.R. = -2.47; p = 0.013), “Insecurity” (ß = -0.52; C.R. = -6.22; p < 0.001), “Falsified patient information” (ß = -0.37; C.R. = -4.50; p < 0.001), “Carelessness” (ß = -0.22; C.R. = -2.55; p = 0.011) and “Drug intake in public” (ß = -0.28; C.R. = -3.06; p = 0.002). In addition, “SDM” only influenced “Reservations” (ß = 0.20; C.R. = 2.55; p = 0.011), “Fear of side effects” (ß = 0.17; C.R. = 2.02; p = 0.043) and “Insecurity” (ß = 0.18; C.R. = 2.43; p =  < 0.001) to a small degree (see Table 7). The R2 value [40] of the constructs representing barriers to medication adherence ranged from 0.04 (“Avoidance of drug side effects”) to 0.24 (“Reservations”) (see Fig. 1).

The construct “Carelessness” significantly predicts “MedAd-” (ß = 0.22; C.R. = 2.70; p = 0.007) and “MedAd + ” (ß = -0.17; C.R. = -2.27; p = 0.023). Moreover, “Reservations” significantly predicts “MedAd + ” (ß = 0.26; C.R. = 2.10; p = 0.036) but does not provide any predictive value for “MedAd-” (ß = -0.09; C.R. = -0.72; p = 0.473).

Furthermore, “PPR” significantly predicts (each p < 0.001) the following first-order dimensions strongly: ßPPR → Communication: information = 0.81; C.R. = 11.55; ßPPR → Communication: patient-centered = 0.79; C.R. = 10.76; ßPPR → Satisfaction medication = 0.81; C.R. = 9.65. As a supplement, “Informedness/Trust” could not be tested for significance (reference variable, set equal to 1). In total, 94% of the variance of “Informedness/Trust”, 62% of the variance of “Communication: patient-centered” and 66% of the variance in “Communication: information” and “Satisfaction medication” was explained by “PPR”. In total, the final model accounted for 20% of the variance in “MedAd + ” (R2 = 0.20) and 12% of the variance in “MedAd-” (R2 = 0.12) (see Fig. 1).

Mediating effects of barriers on “MedAd + ” and “MedAd-” (Hypothesis IV)

Regarding the indirect paths, for the construct “Carelessness”, complete mediation was demonstrated for the prediction of the variable “MedAd-” (beta = -0.05 [-0.230; -0.013]) and partial mediation was demonstrated for the construct “Reservations” for the prediction of the variable “MedAd + ” (beta = -0.15 [-0.465; -0.023]) by “PPR”. For “SDM”, however, no mediating effects were found.

Descriptive statistics

Descriptive statistics for all scales of the “Full path model” are shown in Table 8. “Physician–patient-relationship” (M = 3.47) proved to be “high” from the patient perspective on average. In contrast, “Carelessness” (M = 1.10), “Falsified patient information” (M = 1.21), “Individual decisions” (M = 1.38), “Avoidance of drug side effects” (M = 1.45) and “Drug intake in public” (M = 1.67) were evaluated from their perspective as “low”, and “Insecurity” (M = 2.04), “Reservations” (M = 2.15) and “Fear of side effects” (M = 2.23) were evaluated as “moderate”. The appropriateness of the assumption of a multivariate normal distribution (skewness < 3 [40]) was shown for 8 of the 9 model variables.

Table 8 Descriptive statistics for all scales (N = 225) of the “Full path model”
Full size table

Discussion and conclusion

Discussion

Based on the theoretical model of medication adherence [16] and empirical findings (e.g., [23,24,25, 27, 35]), a structural equation model was developed to examine the associations of several barriers to and facilitators of medication adherence in a sample of people with a high risk of cardiovascular disease.

The latent constructs operationalized in “FF-MedAd-R” questionnaire formed the basis for the specification of the model. After excluding the latent constructs “Forget/mix-up”, “Specific problems” and “Lack of Trust”, all other dimensions in the SEM could be adequately modeled by the empirical data (see Hypothesis I).

In accordance with other empirical findings, patient-centered communication by the physician, sufficient information and trust corresponded to an increase in medication adherence (e.g., [22,23,24,25]). To the best of our knowledge, there have been no empirical findings on patient satisfaction with medication as part of a higher-level construct of PPR. Future research should examine the stability of this finding and the dependence on patient characteristics in more detail.

In contrast, no direct association was shown for forgetting to take medications (“MedAd-”) as a central barrier to medication adherence [25] by “PPR”. In agreement with other study results, forgetting to take medications tends to be unintentional (e.g., [16]) and may be more effectively reduced by other interventions (e.g., establishment of routines, targeted reminder strategies, medication plan [35]). In addition, there was no direct effect of “SDM” to either global item of medication adherence (see Hypothesis II).

Furthermore, it could be shown that a good physician–patient relationship is substantially associated with lower patient-related barriers to medication adherence. Conceivably, a sufficient degree of informedness might reduce reservations, fear of side effects, or insecurities based on contradictory information and might lead to a reduction in independent dose adjustments. Patients who trust their physicians might be less likely to conceal treatment-relevant information from them. In accordance with other study findings [31, 32], we found little evidence of an association between “SDM” and medication adherence. In addition, a positive effect of “SDM” was found only for the dimensions “Reservations”, “Fear of side effects” and “Insecurity”. In accordance with existing study results [31] it is conceivable that people who are confused, such as by inconsistent information, are more likely to participate in the treatment process (seeHypothesis III).

The effect of “PPR” on “MedAd-” proved to be completely mediated by “Carelessness”. This means that a good physician–patient relationship can contribute to reducing careless behavior. In turn, a low level of careless behavior contributes to an increase in regular medication intake.

Furthermore, the effect of “PPR” on “MedAd + ” proved to be partially mediated by “Reservations”. This means that a good physician–patient relationship may not only have a direct positive effect on regular medication intake but also could directly contribute to reducing reservations. Fewer reservations, in turn, may promote the regularity of medication intake. All other mediation hypotheses had to be rejected (see Hypothesis IV).

As a supplementary result, it was noticed that only 6 people with hyperlipoproteinemia and 12 people with hypertension in the study sample stated that they had participated in structured patient education programs in the past (see Table 2), and only approximately 45% of the respondents reported having a written medication plan (see Table 3). This indicates that the prevention potential (e.g., of patient education [25, 27]), especially for people with hypertension and HLP, is not yet sufficiently exploited in the German health care system.

Limitation of this study

The “FF-MedAd-R” questionnaire was used for the first time. Online testing ensured standardized completion conditions. Although we did check the quality criteria, a comprehensive psychometric validation has yet to be conducted (e.g., criterion validity).

All data were self-reported by the respondents. There was no review of the information, e.g., about electronic medical records. In addition, further biases cannot be ruled out (e.g., selection bias, recall bias, information bias, social desirability).

The data stem from a cross-sectional sample. Since Intervention studies can only provide information on causal effects, no causal interpretation of the relationships found in the SEM prediction model is allowed. Although this study examined the associations between multiple barriers and facilitators in predicting medication adherence, causal conclusions should be considered against the background of the theoretical model. There are a number of other influencing factors [31] that could not be examined in this study.

In summary, many items and three dimensions had to be eliminated from the models to reach an acceptable global data fit. Hence, the model definition was to a considerable extent data-driven. Although this modification did not lead to chances in the general definition of the corresponding constructs, it was partly exploratory in nature and requires cross-validation.

In addition, many hypotheses were tested in one data set. This may have led to the problem of alpha error inflation.

The SEM approach applied here did not control for moderator variables and potential sociodemographic or indication-related confounders. Such influences need to be examined in further multigroup analyses of the structural model in larger studies.

The inclusion of additional objective measures would have been useful, especially for the dependent variables "MedAd + " and "MedAd- “.

Using a nationwide self-help organization for data acquisition might have led to limitations in both the representativeness of the sample and the generalizability of the results. Persons unfamiliar with the use of digital media (e.g., elderly people) are likely underrepresented. In contrast, persons with a high education level and those with German citizenship are overrepresented in this sample. It is conceivable that the members of self-help groups are particularly motivated people who may be better informed about a more intensive confrontation with their disease and, therefore, tend to exhibit more medication-adherent behavior.

Conclusion

In summary, the results of this study make an important contribution to theory development and can be used as the basis for developing future interventions in the field of medication adherence in patients experiencing from cardiometabolic diseases. The questionnaire “FF-MedAd-R” has satisfactory reliability and validity (content and construct validity). It is a useful instrument that can be used in everyday clinical practice to measure self-reported medication adherence at multiple levels. The physician–patient relationship was found to be the strongest predictor. The presented findings of construct association should be analyzed in a more differentiated manner. Furthermore, intervention studies should be conducted to critically examine causal inferences and to utilize the findings to improve medication adherence in the clinical practice of patient care.

Practice implications

The questionnaire “FF-MedAd-R” is a multifaceted, time-efficient tool for medical practice that can be used to identify problems in medication adherence in patients experiencing from cardiometabolic diseases on multiple levels and to derive targeted measures. For example, the questionnaire can be used as a template for asking about problems (e.g., fear of side effects, forget) or patient needs (e.g., wish for information) before or during a physician–patient conversation. Problems with the medication could be recorded (e.g., with the aid of a supplementary checklist) and considered for future prescriptions in order to ensure the effectiveness of prescribed medication and increase patient satisfaction with medication. Communication training for physicians can help them learn suitable communication strategies and make better use of the prevention potential of more deliberate relationship management. Patients should be made aware of structured education programs as an option to increase their knowledge and empowerment skills.

When designing future interventions, the concerns and perspectives of patients, physicians, and all other members of the interprofessional teams should be considered in terms of needs, potential for improvement, feasibility, acceptance, and relevance to everyday life.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

References

  1. Fuller RH, Perel P, Navarro-Ruan T, Nieuwlaat R, Haynes RB, Huffman MD. Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart. 2018;104:1238–43. https://doi.org/10.1136/heartjnl-2017-312571.

    Article  PubMed  Google Scholar 

  2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2224–60. https://doi.org/10.1016/S0140-6736(12)61766-8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8. https://doi.org/10.1016/S0140-6736(08)60655-8.

    Article  PubMed  Google Scholar 

  4. Hu FB, Satija A, Manson JE. Curbing the Diabetes Pandemic: The Need for Global Policy Solutions. J AM MED ASSOC. 2015;313:2319–20. https://doi.org/10.1001/jama.2015.5287.

    Article  CAS  Google Scholar 

  5. M. Jecht, Die Therapietreue beeinflussenden Faktoren bei der Einnahme von Diabetesmedikamenten, Diabetologe 2015;11:329–30 [Factors influencing treatment adherence when taking diabetes medications] [in German]. https://doi.org/10.1007/s11428-015-1399-5.

  6. Cholesterol Treatment Trialists' (CTT) Collaboration, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/S0140-6736(14)61368-4.

  7. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–52. https://doi.org/10.1001/archinte.165.10.1147.

    Article  PubMed  Google Scholar 

  8. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the heart and soul study. Arch Intern Med. 2005;165:2508–13. https://doi.org/10.1001/archinte.165.21.2508.

    Article  PubMed  PubMed Central  Google Scholar 

  9. FJA Penning-van Beest, F Termorshuizen, WG Goettsch, OH Klungel, JJP Kastelein, RMC Herings. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28:154–9. https://doi.org/10.1093/eurheartj/ehl391.

  10. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. J Am Med Assoc. 2007;297:177–86. https://doi.org/10.1001/jama.297.2.177.

    Article  CAS  Google Scholar 

  11. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009;169:260–8. https://doi.org/10.1001/archinternmed.2008.552.

    Article  PubMed  Google Scholar 

  12. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. Brit Med J. 2006;333:15. https://doi.org/10.1136/bmj.38875.675486.55.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. J Am Med Assoc Cardiol. 2019;4:206–13. https://doi.org/10.1001/jamacardio.2018.4936.

    Article  Google Scholar 

  14. Kolandaivelu K, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35:3267–76. https://doi.org/10.1093/eurheartj/ehu364.

    Article  CAS  PubMed  Google Scholar 

  15. Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018;115:557–68. https://doi.org/10.3238/arztebl.2018.0557.

    Article  PubMed  PubMed Central  Google Scholar 

  16. World Health Organization, Adherence to long-term therapies. Evidence for action: edited by Eduardo Sabaté, World Health Organization 2003. https://apps.who.int/iris/handle/10665/42682.

  17. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610–8. https://doi.org/10.1097/HJH.0b013e328342ca97.

    Article  CAS  PubMed  Google Scholar 

  18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–30.

    Article  Google Scholar 

  19. Matthes J, Albus C. Improving adherence with medication. Dtsch Arztebl Int. 2014;111:41–7. https://doi.org/10.3238/arztebl.2014.0041.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol. 2015;80:1289–302. https://doi.org/10.1111/bcp.12734.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Heuer HO. Compliance in der Arzneitherapie: Von der Non-Compliance zu pharmazeutischer und medizinischer Kooperation. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1999.

    Google Scholar 

  22. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. https://doi.org/10.3389/fphar.2013.00091.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zolnierek KBH, DiMatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47:826–34. https://doi.org/10.1097/MLR.0b013e31819a5acc.

    Article  PubMed  Google Scholar 

  24. Schäfer C. Patientencompliance. Wiesbaden: Springer; 2020.

    Book  Google Scholar 

  25. K Quaschning, M Koerner, Förderfaktoren und Barrieren der Medikamentenadhärenz von Rehabilitanden mit kardiologischen Erkrankungen – Eine qualitative Befragung, Die Rehabilitation 2021;60:37–44 [Facilitators and Barriers of Medication Adherence of Rehabilitants with Cardiovascular Diseases – A Qualitative Survey] [in German]. https://doi.org/10.1055/a-1242-9562.

  26. Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, Ude M. Medication adherence and persistence according to different antihypertensive drug classes. Int J Cardiol. 2016;220:668–76. https://doi.org/10.1016/j.ijcard.2016.06.263.

    Article  PubMed  Google Scholar 

  27. Tan JP, Cheng KKF, Siah RC-J. A systematic review and meta-analysis on the effectiveness of education on medication adherence for patients with hypertension, hyperlipidaemia and diabetes. J Adv Nurs. 2019;75:2478–94. https://doi.org/10.1111/jan.14025.

    Article  PubMed  Google Scholar 

  28. Thakkar J, Kurup R, Laba T-L, Santo K, Thiagalingam A, Rodgers A, Woodward M, Redfern J, Chow CK. Mobile Telephone text messaging for medication adherence in chronic disease: a meta-analysis. J Am Med Assoc Int Med. 2016;176:340–9. https://doi.org/10.1001/jamainternmed.2015.7667.

    Article  Google Scholar 

  29. Unverzagt S, Meyer G, Mittmann S, Samos F-A, Unverzagt M, Prondzinsky R. Improving treatment adherence in heart failure. Dtsch Arztebl Int. 2016;113:423–30. https://doi.org/10.3238/arztebl.2016.0423.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681–92. https://doi.org/10.1016/s0277-9536(96)00221-3.

    Article  CAS  PubMed  Google Scholar 

  31. Härter M. Gemeinsam entscheiden - erfolgreich behandeln: Neue Wege für Ärzte und Patienten im Gesundheitswesen. Köln: Deutscher Ärzte-Verlag; 2005.

    Google Scholar 

  32. Kashaf MS, McGill ET, Berger ZD. Shared decision-making and outcomes in type 2 diabetes: a systematic review and meta-analysis. Patient Educ Couns. 2017;100:2159–71. https://doi.org/10.1016/j.pec.2017.06.030.

    Article  Google Scholar 

  33. Granger BB, Bosworth H. Medication adherence: emerging use of technology. Curr Opin Cardiol. 2011;26(4):279.

    Article  Google Scholar 

  34. Bosworth HB, Fortmann SP, Kuntz J, Zullig LL, Mendys P, et al. Recommendations for providers on person-centered approaches to assess and improve medication adherence. J Gen Intern Med. 2017;32(1):93–100.

    Article  Google Scholar 

  35. K. Quaschning, M. Koerner, M. Wirtz, Entwicklung und psychometrische Prüfung des „Freiburger Fragebogens zur Medikamentenadhärenz (FF-MedAd)“ bei Rehabilitanden mit kardiologischen Erkrankungen, Rehabilitation 2020;59:26–33 [Development and Psychometric Evaluation of the “Freiburger Fragebogen zur Medikamentenadhärenz (FF-MedAd)“ in a Sample of Rehabilitation Patients with Cardiovascular Diseases] [in German]. https://doi.org/10.1055/a-0883-3856.

  36. SEKiS Baden-Württemberg, Selbsthilfekontaktstellen Baden-Württemberg e. V. https://www.sekis-bw.de/

  37. Tivian XI GmbH., Unipark. Online-Befragungstool. https://www.unipark.com/

  38. Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. Brit Med J Open. 2015;5:e009235. https://doi.org/10.1136/bmjopen-2015-009235.

    Article  Google Scholar 

  39. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7:147–77. https://doi.org/10.1037/1082-989X.7.2.147.

    Article  PubMed  Google Scholar 

  40. Kline RB. Principles and practice of structural equation modeling. 3rd ed. New York: Guilford Press; 2011.

    Google Scholar 

  41. M. Wirtz, Über das Problem fehlender Werte, Rehabilitation 2004;43:109–15 [On the Problem of Missing Data: How to Identify and Reduce the Impact of Missing Data on Findings of Data Analysis] [in German]. https://doi.org/10.1055/s-2003-814839.

  42. Graham JW, Cumsille PE, Elek-Fisk E. Methods for Handling Missing Data. In: Weiner IB, editor. Handbook of psychology. Hoboken: Wiley; 2003.

    Google Scholar 

  43. IBM Corp. Released, IBM SPSS Statistics for Windows. 24th ed. Armonk: IBM Corp; 2016.

    Google Scholar 

  44. Bollen KA. Structural equations with latent variables. 6th ed. New York: Wiley; 1989.

    Google Scholar 

  45. Arbuckle JL. Amos 16.0 User’s Guide. Chicago: Marketing Department SPSS; 2007.

    Google Scholar 

  46. Bühner M. Einführung in die Test- und Fragebogenkonstruktion. 3rd ed. München, Boston: Pearson Studium; 2011.

    Google Scholar 

  47. Bagozzi RP. Principles of marketing research. Cambridge: Blackwell Business; 1996.

    Google Scholar 

  48. Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107:238–46. https://doi.org/10.1037/0033-2909.107.2.238.

    Article  CAS  PubMed  Google Scholar 

  49. Fornell C, Larcker DF. Evaluating structural equation models with unobservable variables and measurement error. J Mark Res. 1981;18:39–50. https://doi.org/10.2307/3151312.

    Article  Google Scholar 

  50. Hair JF, Black WC, Babin BJ, Anderson RE. Multivariate data analysis. Harlow: Pearson Education Limited; 2014.

    Google Scholar 

  51. MacKinnon DP. Introduction to statistical mediation analysis. New York: Routledge, Taylor & Francis Group; 2013.

    Google Scholar 

  52. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40:879–91. https://doi.org/10.3758/BRM.40.3.879.

    Article  PubMed  Google Scholar 

  53. Eid M, Gollwitzer M, Schmitt M. Statistik und Forschungsmethoden: Mit Online-Materialien. 5th ed. Weinheim: Beltz; 2017.

    Google Scholar 

Download references

Acknowledgements

The study is part of the project entitled “Increasing medication adherence to improve patient safety in cardiological rehabilitation (PaSiMed)” in Germany. We would like to thank the “State Working Group of Contact and Information Centers for Self-Help Groups in Baden-Württemberg (SEKiS)” for their support and all patients who participated.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Author information

Authors and Affiliations

  1. Institute of Medical Psychology and Medical Sociology, Faculty of Medicine, University of Freiburg, Hebelstraße 29, 79104, Freiburg, Germany

    Katharina Quaschning & Mirjam Koerner

  2. Department of Research Methods in the Health Sciences, Institute of Everyday Culture, Sports and Health, University of Education Freiburg, Kunzenweg 21, 79117, Freiburg, Germany

    Markus Antonius Wirtz

Authors
  1. Katharina Quaschning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mirjam Koerner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Antonius Wirtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KQ defined the design of the study, collected the data, analyzed and interpreted the data and prepared the first draft of the manuscript. MK supported the first author by reading the manuscript critically and providing relevant comments. MAW contributed to the design of the study; assisted in data analysis, interpretation of the results, and editing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Katharina Quaschning.

Ethics declarations

Ethics approval and consent to participate

Ethics approval for this study was obtained from the ethical committee of the University of Freiburg, Germany (vote no.: 544/16). The study was registered with the German Clinical Trials Register (DRKS00011134). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants of the study after being informed about the study purpose, procedure and confidentiality of the data collected.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. The authors confirm that all authors have approved the manuscript for submission and the content of the manuscript has not been published or submitted for publication elsewhere.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quaschning, K., Koerner, M. & Wirtz, M.A. Analyzing the effects of barriers to and facilitators of medication adherence among patients with cardiometabolic diseases: a structural equation modeling approach. BMC Health Serv Res 22, 588 (2022). https://doi.org/10.1186/s12913-022-07987-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12913-022-07987-3

Keywords

BMC Health Services Research

ISSN: 1472-6963

Contact us